Global T-Cell Therapy Market - Distribution by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.

Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates. Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) - Global Forecast 2022-2035” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
A detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TIL, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
Elaborate profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
An analysis of various type of partnership that have been inked between several stakeholders in the domain of T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
An in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
Elaborate profiles of the several leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several relevant parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America, Europe, Asia Pacific, Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following individuals:

Tim Oldham (Former Chief Executive Officer, Cell Therapies)
Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
Miguel Forte (Chief Operating Officer, TxCell)
Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
Peter Ho (Former Director, Process Development, Iovance Biotherapeutics)
Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

What are the prevalent R&D trends related to T-cell immunotherapies (specifically CAR-Ts, TCRs and TILs)?
What kind of clinical conditions can be treated using T-cell immunotherapies?
Who are the leading industry and non-industry players in this market?
In which geographies extensive research on T-cell immunotherapy is being conducted?
What kind of partnership models are commonly adopted by industry stakeholders?
Who are the key investors in T-cell immunotherapy domain?
Who are the key opinion leaders / experts from renowned academic and research institutes who can help drive product development efforts in this domain?
How is the intellectual property landscape for global T-cell therapies likely to evolve in the foreseen future?
Who are the key service providers (CMOs / CDMOs) with capabilities to develop and manufacture T-cell therapies?
What are the key factors that are likely to influence the evolution of the T-cell immunotherapies market?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the key promotional strategies used by companies having marketed products?

1. PREFACE

1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.7. Challenges Associated with Use of CAR-T Cell Therapies
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. Development History
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR Therapy
3.8.4. Comparison of CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. Development History
3.9.2. Development of TILs Therapy
3.10. Key Benefits and Roadblocks
3.11. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indications
4.2.6. Analysis by Key Target Antigens
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies
4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. TCR-BASED THERAPIES: MARKET LANDSCAPE

5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Phase of Development and Therapeutic Area
5.2.5. Analysis by Key Target Indication
5.2.6. Analysis by Key Target Antigen
5.2.7. Analysis by Source of T-Cells
5.2.8. Analysis by Route of Administration
5.2.9. Analysis by Phase of Development and Route of Administration
5.2.10. Analysis by Dosing Frequency
5.2.11. Analysis by Target Patient Segment
5.2.12. Analysis by Type of Therapy
5.2.13. Analysis by Phase of Development and Type of Therapy
5.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
5.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies
5.3. TCR-based Therapies: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. TIL-BASED THERAPIES: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
6.2.1. Analysis by Type of Developer
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Key Target Indication
6.2.5. Analysis by Source of T-Cells
6.2.6. Analysis by Route of Administration
6.2.7. Analysis by Dosing Frequency
6.2.8. Analysis by Target Patient Segment
6.2.9. Analysis by Type of Therapy
6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
6.3. TIL-based Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS

7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors
7.3. T-Cell Immunotherapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis by Trial Phase and Enrolled Patient Population
8.3.7. Analysis by Target Patient Segment
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.3.13. Analysis of Clinical Trials by Geography
8.3.14. Analysis of Enrolled Patient Population by Geography
8.4. TCR-based Therapies: Clinical Trial Analysis
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.4.3. Analysis by Trial Status
8.4.4. Analysis by Trial Registration Year and Trial Status
8.4.5. Analysis by Trial Phase
8.4.6. Analysis by Trial Phase and Enrolled Patient Population
8.4.7. Analysis by Target Patient Segment
8.4.8. Analysis by Type of Sponsor / Collaborator
8.4.9. Analysis by Study Design
8.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.4.13. Analysis of Clinical Trials by Geography
8.4.14. Analysis of Enrolled Patient Population by Geography
8.5. TIL-based Therapies: Clinical Trial Analysis
8.5.1. Analysis by Trial Registration Year
8.5.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.5.3. Analysis by Trial Status
8.5.4. Analysis by Trial Registration Year and Trial Status
8.5.5. Analysis by Trial Phase
8.5.6. Analysis by Trial Phase and Enrolled Patient Population
8.5.7. Analysis by Target Patient Segment
8.5.8. Analysis by Type of Sponsor / Collaborator
8.5.9. Analysis by Study Design
8.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.5.13. Analysis of Clinical Trials by Geography
8.5.14. Analysis of Enrolled Patient Population by Geography

9. KEY OPINION LEADERS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Qualification
9.4.4. Analysis by Geographical Location of KOLs
9.4.5. KOL Activeness versus KOL Strength
9.4.6. Most Prominent KOLs: Analysis by RA score
9.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.5. TCR-based Therapies: Key Opinion Leaders
9.5.1. Analysis by Type of Organization
9.5.2. Analysis by Affiliated Organization
9.5.3. Analysis by Qualification
9.5.4. Analysis by Geographical Location of KOLs
9.5.5. KOL Activeness versus KOL Strength
9.5.6. Most Prominent KOLs: Analysis by RA score
9.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.6. TIL-based Therapies: Key Opinion Leaders
9.6.1. Analysis by Type of Organization
9.6.2. Analysis by Affiliated Organization
9.6.3. Analysis by Qualification
9.6.4. Analysis by Geographical Location of KOLs
9.6.5. KOL Activeness versus KOL Strength
9.6.6. Most Prominent KOLs: Analysis by RA score
9.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. CAR-T CELL THERAPY PROFILES

10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
10.2.1. Therapy Overview
10.2.2. Clinical Trial Information
10.2.3. Clinical Trial Endpoints
10.2.4. Clinical Trial Results
10.2.5. Estimated Sales Revenues
10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
10.3.1. Therapy Overview
10.3.2. Clinical Trial Information
10.3.3. Clinical Trial Endpoints
10.3.4. Clinical Trial Results
10.3.5. Estimated Sales Revenues
10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
10.4.1. Therapy Overview
10.4.2. Clinical Trial Information
10.4.3. Clinical Trial Endpoints
10.4.4. Clinical Trial Results
10.4.5. Estimated Sales Revenues
10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
10.5.1. Therapy Overview
10.5.2. Clinical Trial Information
10.5.3. Clinical Trial Endpoints
10.5.4. Clinical Trial Results
10.5.5. Estimated Sales Revenues
10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
10.6.1. Therapy Overview
10.6.2. Clinical Trial Information
10.6.3. Clinical Trial Endpoints
10.6.4. Clinical Trial Results
10.6.5. Estimated Sales Revenues
10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
10.7.1. Therapy Overview
10.7.2. Clinical Trial Information
10.7.3. Clinical Trial Endpoints
10.7.4. Clinical Trial Results
10.7.5. Estimated Sales Revenues
10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
10.8.1. Therapy Overview
10.8.2. Clinical Trial Information
10.8.3. Clinical Trial Endpoints
10.8.4. Clinical Trial Results
10.8.5. Estimated Sales Revenues
10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
10.9.1. Therapy Overview
10.9.2. Clinical Trial Information
10.9.3. Clinical Trial Endpoints
10.9.4. Estimated Sales Revenues
10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
10.10.1. Therapy Overview
10.10.2. Clinical Trial Information
10.10.3. Clinical Trial Endpoints
10.10.4. Clinical Trial Results
10.10.5. Estimated Sales Revenues
10.11. AUTO3 / CD19/22 CAR-T (Autolus)
10.11.1. Therapy Overview
10.11.2. Clinical Trial Information
10.11.3. Clinical Trial Endpoints
10.11.4. Clinical Trial Results
10.11.5. Estimated Sales Revenues

11. TCR-BASED THERAPY PROFILES

11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
11.2.1. Therapy Overview
11.2.2. Clinical Trial Information
11.2.3. Clinical Trial Endpoints
11.2.4. Clinical Trial Results
11.2.5. Estimated Sales Revenues
11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
11.3.1. Therapy Overview
11.3.2. Clinical Trial Information
11.3.3. Clinical Trial Endpoints
11.3.4. Clinical Trial Results
11.3.5. Estimated Sales Revenues
11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
11.4.1. Therapy Overview
11.4.2. Clinical Trial Information
11.4.3. Clinical Trial Endpoints
11.4.4. Clinical Trial Results
11.4.5. Estimated Sales Revenues
11.5. JTCR016 (Juno Therapeutics)
11.5.1. Therapy Overview
11.5.2. Clinical Trial Information
11.5.3. Clinical Trial Endpoints
11.5.4. Estimated Sales Revenues
11.6. TBI-1301 (Takara Bio)
11.6.1. Therapy Overview
11.6.2. Clinical Trial Information
11.6.3. Clinical Trial Endpoints
11.6.4. Clinical Trial Results
11.6.5. Estimated Sales Revenues
11.7. MDG1011 (Medigene)
11.7.1. Therapy Overview
11.7.2. Clinical Trial Information
11.7.3. Clinical Trial Endpoints
11.7.4. Clinical Trial Results
11.7.5. Estimated Sales Revenues

12. TIL-BASED THERAPY PROFILES

12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
12.2.1. Therapy Overview
12.2.2. Clinical Trial Information
12.2.3. Clinical Trial Endpoints
12.2.4. Clinical Trial Results
12.2.5. Estimated Sales Revenues
12.3. LN-145 (Iovance Biotherapeutics)
12.3.1. Therapy Overview
12.3.2. Clinical Trial Information
12.3.3. Clinical Trial Endpoints
12.3.4. Clinical Trial Results
12.3.5. Estimated Sales Revenues
12.4. ITIL-168 (Instil Bio)
12.4.1. Therapy Overview
12.4.2. Clinical Trial Information
12.4.3. Clinical Trial Endpoints
12.4.4. Clinical Trial Results
12.4.5. Estimated Sales Revenues
12.5. LTX-315 (Lytix Biopharma)
12.5.1. Therapy Overview
12.5.2. Clinical Trial Information
12.5.3. Clinical Trial Endpoints
12.5.4. Clinical Trial Results
12.5.5. Estimated Sales Revenues

13. EMERGING TECHNOLOGIES

13.1. Chapter Overview
13.2. Genome Editing Technologies
13.2.1. Technology Overview
13.2.2. Applications of Genome Editing Technologies
13.2.3. Emerging Technology Platforms for T-Cell Therapies
13.2.3.1. CRISPR / CAS9 System
13.2.3.1.1. Key Components
13.2.3.1.2. Mechanism of Action
13.2.3.1.3. Targeting Efficiency and Challenges
13.2.3.1.4. Next-Gen CRISPR Technology
13.2.3.1.5. Technology Providers
13.2.3.1.5.1. Intellia Therapeutics
13.2.3.1.5.2. Editas Medicine
13.2.3.1.5.3. CRISPR Therapeutics
13.2.3.1.5.4. Beam Therapeutics
13.2.3.1.5.5. Gracell Technologies
13.2.3.1.5.6. Caribou Biosciences
13.2.3.1.5.7. Nanjing Bioheng Biotech
13.2.3.1.5.8. Intima Biosciences
13.2.3.1.5.9. KSQ Therapeutics
13.2.3.1.5.10. Refuge Biotechnologies
13.2.3.2. TALENS
13.2.3.2.1. Key Components and Function
13.2.3.2.2. Mechanism of Action
13.2.3.2.3. Advantages and Challenges
13.2.3.2.4. Technology Providers
13.2.3.2.4.1. Cellectis
13.2.3.2.4.2. Editas Medicine
13.2.3.3. MegaTAL
13.2.3.3.1. Mechanism of Action
13.2.3.3.2. Technology Providers
13.2.3.3.2.1. bluebird bio
13.2.3.3.2.2. Precision Biosciences
13.2.3.4. Zinc Finger Nuclease
13.2.3.4.1. Mechanism of Action
13.2.3.4.2. Technology Providers
13.2.3.4.2.1. Sangamo Therapeutics
13.2.4. Competitive Analysis: Gene Editing Platforms
13.3. Designing T-Cell Therapies with Improved Characteristics
13.3.1. Technologies for Targeting Multiple Cancers
13.3.1.1. Antibody Coupled T-Cell Receptor
13.3.1.1.1. Cogent Biosciences
13.3.1.2. NKR-T Platform
13.3.1.2.1. Celyad
13.3.1.2.2. Glycostem
13.3.1.2.3. CatamaranBio
13.3.2. Technologies for Improved Safety
13.3.2.1. Armored CAR and EGFRt Technology
13.3.2.1.1. Juno Therapeutics
13.3.2.2. Rheoswitch Therapeutic System
13.3.2.2.1. Intrexon
13.3.2.2.2. Precigen
13.3.2.3. Inducible Caspase 9 Safety Switch
13.3.2.3.1. Bellicum Pharmaceuticals
13.3.2.3.1.1. CaspaCIDe Technology
13.3.2.3.1.2. CIDeCAR Technology
13.3.2.3.1.3. GoCAR-T Technology
13.3.2.4. On-OFF Switch, Multiple Companies
13.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
13.3.2.4.2. On-OFF Switch (Theravectys)
13.3.2.5. Other Technologies to Improve CAR-T Safety
13.3.3. Allogeneic Technologies
13.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
13.3.3.2. Allogeneic Platform (CELYAD)
13.3.3.3. Allogeneic Platform (Cellectis)
13.3.3.4. AlloCAR T (Allogene Therapeutics)
13.4. Future Perspectives

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Type of Product
14.3.4. Analysis by Year of Partnership and Type of Product
14.3.5. Analysis by Type of Partnership and Type of Product
14.3.6. Analysis by Type of Partner
14.3.7. Analysis by Type of Product and Type of Partner
14.3.8. Most Popular Products: Analysis by Number of Partnerships
14.3.9. Most Active Industry Players: Analysis by Number of Partnerships
14.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
14.3.11. Analysis by Geography
14.3.11.1. Intercontinental and Intracontinental Agreements
14.3.11.2. International and Local Deals

15. FUNDING AND INVESTMENT ANALYSIS

15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
15.3.1. Analysis of Instances by Year
15.3.2. Analysis of Amount Invested by Year
15.3.3. Analysis by Type of Funding
15.3.4. Analysis of Amount Invested across Different Types of Therapies
15.3.5. Analysis by Type of Investor
15.3.6. Most Active Players: Analysis by Number of Instances
15.3.7. Most Active Investors: Analysis by Amount Invested
15.3.8. Analysis of Amount Invested by Geography
15.3.9. Most Active Investors: Analysis by Number of Funding Instances

16. PATENT ANALYSIS

16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
16.4.1. Analysis by Patent Publication Year
16.4.2. Analysis by Patent Application Year
16.4.3. Analysis by Geography
16.4.4. Analysis by Type of Player
16.4.5. Analysis by CPC Symbols
16.4.6. Analysis by Key Focus Area
16.4.7. Leading Players: Analysis by Number of Patents
16.4.8. Car-T Cell Therapies: Patent Benchmarking
16.4.9. Analysis By Patent Characteristics
16.4.10. Car-T Cell Therapies: Patent Valuation
16.5. TCR- based Therapies
16.5.1. Analysis by Patent Publication Year
16.5.2. Analysis By Patent Application Year
16.5.3. Analysis by Geography
16.5.4. Analysis by Type of Player
16.5.5. Analysis by CPC Symbols
16.5.6. Analysis by Key Focus Area
16.5.7. Leading Player: Analysis by Number of Patents
16.5.8. TCR-based Therapies: Patent Benchmarking
16.5.9. Analysis By Patent Characteristics
16.5.10. TCR-based Cell Therapies: Patent Valuation
16.6. TIL- based Therapies
16.6.1. Analysis by Patent Publication Year
16.6.2. Analysis By Patent Application Year
16.6.3. Analysis by Geography
16.6.4. Analysis by Type of Player
16.6.5. Analysis by CPC Symbols
16.6.6. Analysis by Key Focus Area
16.6.7. Leading Player: Analysis by Number of Patents
16.6.8. TIL-based Therapies: Patent Benchmarking
16.6.9. Analysis By Patent Characteristics
16.6.10. TIL-based Therapies: Patent Valuation

17. OTHER T-CELL IMMUNOTHERAPIES

17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
17.2.1. Fucosylated T-Cell Therapies
17.2.2. Gamma Delta T-Cell Therapies
17.2.3. PD-1 Knockout Engineered T-Cell Therapies
17.2.4. TAC T-Cell Therapies
17.2.5. T-Cell Vaccines
17.2.6. Treg Cell Therapies
17.2.7. Virus-Driven T-Cell Therapies
17.3. Other T-Cell Immunotherapies: Market Overview
17.3.1. Analysis by Type of T-Cell
17.3.2. Analysis by Source of T-Cell
17.3.3. Analysis by Phase of Development
17.3.4. Analysis by Therapeutic Area
17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks

18. CASE STUDY: CELL THERAPY MANUFACTURING

18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
18.3.1. Centralized Manufacturing Model
18.3.2. Decentralized Manufacturing Model
18.4. Scalability of Cell Therapy Manufacturing Processes
18.4.1. Scale-Up
18.4.2. Scale-Out
18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies
18.7. Important Factors for Cell Therapy Manufacturing
18.7.1. Characterization
18.7.2. Cost of Goods
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives

19. COST PRICE ANALYSIS

19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
19.3.1. Based on Associated Costs
19.3.2. Based on Availability of Competing Products
19.3.3. Based on Patient Segment
19.3.4. Based on Opinions of Industry Experts
19.4. Reimbursement related Considerations for T-Cell Immunotherapies
19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions And Forecast Methodology
20.4. Overall T-Cell Immunotherapy Market, 2022-2035
20.4.1. T-Cell Immunotherapy Market: Analysis by Type of Therapy
20.4.2. T-Cell Immunotherapy Market: Analysis by Target Indication
20.4.3. T-Cell Immunotherapy Market: Analysis by Target Antigen
20.4.4. T-Cell Immunotherapy Market: Analysis by Key Players
20.4.5. T-Cell Immunotherapy Market: Analysis by Geography
20.5. T-Cell Immunotherapy Market: Value Creation Analysis
20.6. Overall CAR-T Cell Therapies Market, 2022-2035
20.6.1. CAR-T Cell Therapies Market: Analysis by Target Indication
20.6.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
20.6.3. CAR-T Cell Therapies Market: Analysis by Key Players
20.6.4. CAR-T Cell Therapies Market: Analysis by Geography
20.6.5. Product Wise Sales Forecast
20.6.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
20.6.5.1.1. Sales Forecast (USD Million)
20.6.5.1.2. Net Present Value
20.6.5.1.3. Value Creation Analysis
20.6.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
20.6.5.2.1. Sales Forecast (USD Million)
20.6.5.2.2. Net Present Value (USD Million)
20.6.5.2.3. Value Creation Analysis
20.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
20.6.5.3.1. Sales Forecast (USD Million)
20.6.5.3.2. Net Present Value (USD Million)
20.6.5.3.3. Value Creation Analysis
20.6.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
20.6.5.4.1. Sales Forecast (USD Million)
20.6.5.4.2. Net Present Value (USD Million)
20.6.5.4.3. Value Creation Analysis
20.6.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
20.6.5.5.1. Sales Forecast (USD Million)
20.6.5.5.2. Net Present Value (USD Million)
20.6.5.5.3. Value Creation Analysis
20.6.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
20.6.5.6.1. Sales Forecast (USD Million)
20.6.5.6.2. Net Present Value (USD Million)
20.6.5.6.3. Value Creation Analysis
20.6.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
20.6.5.7.1. Sales Forecast (USD Million)
20.6.5.7.2. Net Present Value (USD Million)
20.6.5.7.3. Value Creation Analysis
20.6.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.8.1. Sales Forecast (USD Million)
20.6.5.8.2. Net Present Value (USD Million)
20.6.5.8.3. Value Creation Analysis
20.6.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
20.6.5.9.1. Sales Forecast (USD Million)
20.6.5.9.2. Net Present Value (USD Million)
20.6.5.9.3. Value Creation Analysis
20.6.5.10. Descartes-11 (Cartesian Therapeutics)
20.6.5.10.1. Sales Forecast (USD Million)
20.6.5.10.2. Net Present Value (USD Million)
20.6.5.10.3. Value Creation Analysis
20.6.5.11. Descartes-08 (Cartesian Therapeutics)
20.6.5.11.1. Sales Forecast (USD Million)
20.6.5.11.2. Net Present Value (USD Million)
20.6.5.11.3. Value Creation Analysis
20.6.5.12. Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine)
20.6.5.12.1. Sales Forecast (USD Million)
20.6.5.12.2. Net Present Value (USD Million)
20.6.5.12.3. Value Creation Analysis
20.6.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
20.6.5.13.1. Sales Forecast (USD Million)
20.6.5.13.2. Net Present Value (USD Million)
20.6.5.13.3. Value Creation Analysis
20.6.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
20.6.5.14.1. Sales Forecast (USD Million)
20.6.5.14.2. Net Present Value (USD Million)
20.6.5.14.3. Value Creation Analysis
20.6.5.15. TAK-007 (Takeda)
20.6.5.15.1. Sales Forecast (USD Million)
20.6.5.15.2. Net Present Value (USD Million)
20.6.5.15.3. Value Creation Analysis
20.6.5.16. AUTO1 (Autolus)
20.6.5.16.1. Sales Forecast (USD Million)
20.6.5.16.2. Net Present Value (USD Million)
20.6.5.16.3. Value Creation Analysis
20.6.5.17. AUTO3 (Autolus)
20.6.5.17.1. Sales Forecast (USD Million)
20.6.5.17.2. Net Present Value (USD Million)
20.6.5.17.3. Value Creation Analysis
20.6.5.18. CD19-CAR-T (Bioray Laboratories)
20.6.5.18.1. Sales Forecast (USD Million)
20.6.5.18.2. Net Present Value (USD Million)
20.6.5.18.3. Value Creation Analysis
20.6.5.19. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.19.1. Sales Forecast (USD Million)
20.6.5.19.2. Net Present Value (USD Million)
20.6.5.19.3. Value Creation Analysis
20.6.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
20.6.5.20.1. Sales Forecast (USD Million)
20.6.5.20.2. Net Present Value (USD Million)
20.6.5.20.3. Value Creation Analysis
20.6.5.21. CCT301 CAR-T (Shanghai PerHum Therapeutics)
20.6.5.21.1. Sales Forecast (USD Million)
20.6.5.21.2. Net Present Value (USD Million)
20.6.5.21.3. Value Creation Analysis
20.6.5.22. BinD19 (Shenzhen BinDeBio)
20.6.5.22.1. Sales Forecast (USD Million)
20.6.5.22.2. Net Present Value (USD Million)
20.6.5.22.3. Value Creation Analysis
20.6.5.23. CARCIK-CD19 (CoImmune)
20.6.5.23.1. Sales Forecast (USD Million)
20.6.5.23.2. Net Present Value (USD Million)
20.6.5.23.3. Value Creation Analysis
20.6.5.24. PBCAR269A (Precision BioSciences / Servier)
20.6.5.24.1. Sales Forecast (USD Million)
20.6.5.24.2. Net Present Value (USD Million)
20.6.5.24.3. Value Creation Analysis
20.6.5.25. CD123 CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.25.1. Sales Forecast (USD Million)
20.6.5.25.2. Net Present Value (USD Million)
20.6.5.25.3. Value Creation Analysis
20.6.5.26. BCMA CAR-T (Chongqing Precision Biotechnology)
20.6.5.26.1. Sales Forecast (USD Million)
20.6.5.26.2. Net Present Value (USD Million)
20.6.5.26.3. Value Creation Analysis
20.6.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.27.1. Sales Forecast (USD Million)
20.6.5.27.2. Net Present Value (USD Million)
20.6.5.27.3. Value Creation Analysis
20.6.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
20.6.5.28.1. Sales Forecast (USD Million)
20.6.5.28.2. Net Present Value (USD Million)
20.6.5.28.3. Value Creation Analysis
20.6.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
20.6.5.29.1. Sales Forecast (USD Million)
20.6.5.29.2. Net Present Value (USD Million)
20.6.5.29.3. Value Creation Analysis
20.6.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
20.6.5.30.1. Sales Forecast (USD Million)
20.6.5.30.2. Net Present Value (USD Million)
20.6.5.30.3. Value Creation Analysis
20.6.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
20.6.5.31.1. Sales Forecast (USD Million)
20.6.5.31.2. Net Present Value (USD Million)
20.6.5.31.3. Value Creation Analysis
20.6.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
20.6.5.32.1. Sales Forecast (USD Million)
20.6.5.32.2. Net Present Value (USD Million)
20.6.5.32.3. Value Creation Analysis
20.6.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
20.6.5.33.1. Sales Forecast (USD Million)
20.6.5.33.2. Net Present Value (USD Million)
20.6.5.33.3. Value Creation Analysis
20.6.5.34. CT053 (CARsgen Therapeutics)
20.6.5.34.1. Sales Forecast (USD Million)
20.6.5.34.2. Net Present Value (USD Million)
20.6.5.34.3. Value Creation Analysis
20.6.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
20.6.5.35.1. Sales Forecast (USD Million)
20.6.5.35.2. Net Present Value (USD Million)
20.6.5.35.3. Value Creation Analysis
20.6.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.36.1. Sales Forecast (USD Million)
20.6.5.36.2. Net Present Value (USD Million)
20.6.5.36.3. Value Creation Analysis
20.6.5.37. ALLO-605 (Allogene Therapeutics)
20.6.5.37.1. Sales Forecast (USD Million)
20.6.5.37.2. Net Present Value (USD Million)
20.6.5.37.3. Value Creation Analysis
20.6.5.38. WU CART 007 (Wugen)
20.6.5.38.1. Sales Forecast (USD Million)
20.6.5.38.2. Net Present Value (USD Million)
20.6.5.38.3. Value Creation Analysis
20.6.5.39. CT103A (Nanjing IASO Biotherapeutics)
20.6.5.39.1. Sales Forecast (USD Million)
20.6.5.39.2. Net Present Value (USD Million)
20.6.5.39.3. Value Creation Analysis
20.7. Overall TCR-based Therapies Market
20.7.1. TCR-Based Therapies Market: Analysis by Target Indication
20.7.2. TCR-Based Therapies Market: Analysis by Target Antigen
20.7.3. TCR-Based Therapies Market: Analysis by Key Players
20.7.4. TCR-Based Therapies Market: Analysis by Geography
20.7.5. Product Wise Sales Forecast
20.7.5.1 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore)
20.7.5.1.1. Sales Forecast (USD Million)
20.7.5.1.2. Net Present Value (USD Million)
20.7.5.1.3. Value Creation Analysis
20.7.5.2. GSK3377794 (GlaxoSmithKline)
20.7.5.2.1. Sales Forecast (USD Million)
20.7.5.2.2. Net Present Value (USD Million)
20.7.5.2.3. Value Creation Analysis
20.7.5.3. YT-E001 (China Immunotech)
20.7.5.3.1. Sales Forecast (USD Million)
20.7.5.3.2. Net Present Value (USD Million)
20.7.5.3.3. Value Creation Analysis
20.7.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
20.7.5.4.1. Sales Forecast (USD Million)
20.7.5.4.2. Net Present Value (USD Million)
20.7.5.4.3. Value Creation Analysis
20.7.5.5. EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma)
20.7.5.5.1. Sales Forecast (USD Million)
20.7.5.5.2. Net Present Value (USD Million)
20.7.5.5.3. Value Creation Analysis
20.7.5.6. NTLA-5001 (Intellia Therapeutics)
20.7.5.6.1. Sales Forecast (USD Million)
20.7.5.6.2. Net Present Value (USD Million)
20.7.5.6.3. Value Creation Analysis
20.7.5.7. TBI-1301 (Takara Bio)
20.7.5.7.1. Sales Forecast (USD Million)
20.7.5.7.2. Net Present Value (USD Million)
20.7.5.7.3. Value Creation Analysis
20.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
20.7.5.8.1. Sales Forecast (USD Million)
20.7.5.8.2. Net Present Value (USD Million)
20.7.5.8.3. Value Creation Analysis
20.7.5.9. FH-MCVA2TCR (TCRCure Biopharma)
20.7.5.9.1. Sales Forecast (USD Million)
20.7.5.9.2. Net Present Value (USD Million)
20.7.5.9.3. Value Creation Analysis
20.8. Overall TIL-Based Therapies Market
20.8.1. TIL-Based Therapies Market: Analysis by Target Indication
20.8.2. TIL-Based Therapies Market: Analysis by Key Players
20.8.3. TIL-Based Therapies Market: Analysis by Geography
20.8.3.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
20.8.3.1.1. Sales Forecast (USD Million)
20.8.3.1.2. Net Present Value (USD Million)
20.8.3.1.3. Value Creation Analysis
20.8.3.2. LN-145 (Iovance Biotherapeutics)
20.8.3.2.1. Sales Forecast (USD Million)
20.8.3.2.2. Net Present Value (USD Million)
20.8.3.2.3. Value Creation Analysis
20.8.3.3. LTX-315 and TILs (Lytix Biopharma)
20.8.3.3.1. Sales Forecast (USD Million)
20.8.3.3.2. Net Present Value (USD Million)
20.8.3.3.3. Value Creation Analysis
20.8.3.4. TILs (Prometheus Laboratories)
20.8.3.4.1. Sales Forecast (USD Million)
20.8.3.4.2. Net Present Value (USD Million)
20.8.3.4.3. Value Creation Analysis
20.8.3.5. Donor Lymphocyte Infusion (Incyte)
20.8.3.5.1. Sales Forecast (USD Million)
20.8.3.5.2. Net Present Value (USD Million)
20.8.3.5.3. Value Creation Analysis
20.8.3.6. ITIL-168 (Instil Bio)
20.8.3.6.1. Sales Forecast (USD Million)
20.8.3.6.2. Net Present Value (USD Million)
20.8.3.6.3. Value Creation Analysis
20.8.3.7. IOV-2001 (Iovance Biotherapeutics)
20.8.3.7.1. Sales Forecast (USD Million)
20.8.3.7.2. Net Present Value (USD Million)
20.8.3.7.3. Value Creation Analysis
20.8.3.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
20.8.3.8.1. Sales Forecast (USD Million)
20.8.3.8.2. Net Present Value (USD Million)
20.8.3.8.3. Value Creation Analysis
20.8.3.9. TILs (Bristol-Myers Squibb)
20.8.3.9.1. Sales Forecast (USD Million)
20.8.3.9.2. Net Present Value (USD Million)
20.8.3.9.3. Value Creation Analysis

21. PROMOTIONAL ANALYSIS

21.1. Chapter Overview
21.2. Channels Used for Promotional Campaigns
21.3. Summary of Product Website Analysis
21.4. Summary of Patient Support Services and Informative Downloads
21.5. Kymriah: Promotional Analysis
21.5.1. Drug Overview
21.5.2. Product Website Analysis
21.5.2.3. Informative Downloads
21.5.3. Patient Support Services
21.6. Yescarta: Promotional Analysis
21.6.1. Drug Overview
21.6.2. Product Website Analysis
21.6.2.3. Informative Downloads
21.6.3. Patient Support Services
21.7. Tecartus: Promotional Analysis
21.7.1. Drug Overview
21.7.2. Product Website Analysis
21.7.3. Patient Support Services
21.8. Breyanzi: Promotional Analysis
21.8.1. Drug Overview
21.8.2. Product Website Analysis
21.8.3. Patient Support Services
21.9. Abecma: Promotional Analysis
21.9.1. Drug Overview
21.9.2. Product Website Analysis
21.9.3. Patient Support Services
21.10. Carvykti: Promotional Analysis
21.10.1. Drug Overview
21.10.2. Product Website Analysis
21.10.3. Patient Support Services
21.11. Kimmtrak: Promotional Analysis
21.11.1. Drug Overview
21.11.2. Product Website Analysis
21.11.3. Patient Support Services

22. COMPANY PROFILES

22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview
24.2. Cell Therapies
24.2.1. Interview Transcript: Tim Oldham, Former Chief Executive Officer
24.3. Glycostem Therapeutics
24.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
24.4. Gracell Biotechnologies
24.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
24.5. Lion TCR
24.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
24.6. TxCell
24.6.1. Interview Transcript: Miguel Forte, Chief Executive Officer
24.7. Kite Pharma
24.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
24.8. Celyad
24.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
24.9. Iovance Biotherapeutics
24.9.1. Interview Transcript: Peter Ho, Former Director, Process Development
24.10. Waisman Biomanufacturing
24.10.1. Interview Transcript: Brian Dattilo, Director, Business Development
24.11. Theravectys
24.11.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
24.12. Changhai Hospital
24.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
24.13. University of Colorado
24.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

25. APPENDIX 1: TABULATED DATA26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary (CAR-T Cell Therapies): Overall Market Landscape
Figure 2.2 Executive Summary (CAR-T Cell Therapies): Clinical Trial Analysis
Figure 2.3 Executive Summary (CAR-T Cell Therapies): Key Opinion Leaders
Figure 2.4 Executive Summary (CAR-T Cell Therapies): Partnerships and Collaborations
Figure 2.5 Executive Summary (CAR-T Cell Therapies): Funding and Investments
Figure 2.6 Executive Summary (CAR-T Cell Therapies): Patent Analysis
Figure 2.7 Executive Summary (CAR-T Cell Therapies): Market Forecast and Opportunity Analysis
Figure 2.8 Executive Summary (TCR-based Therapies): Overall Market Landscape
Figure 2.9 Executive Summary (TCR-based Therapies): Clinical Trial Analysis
Figure 2.10 Executive Summary (TCR-based Therapies): Key Opinion Leaders
Figure 2.11 Executive Summary (TCR-based Therapies): Partnerships and Collaborations
Figure 2.12 Executive Summary (TCR-based Therapies): Funding and Investments
Figure 2.13 Executive Summary (TCR-based Therapies): Patent Analysis
Figure 2.14 Executive Summary (TCR-based Therapies): Market Forecast and Opportunity Analysis
Figure 2.15 Executive Summary (TIL-based Therapies): Overall Market Landscape
Figure 2.16 Executive Summary (TIL-based Therapies): Clinical Trial Analysis
Figure 2.17 Executive Summary (TIL-based Therapies): Key Opinion Leaders
Figure 2.18 Executive Summary (TIL-based Therapies): Partnerships and Collaborations
Figure 2.19 Executive Summary (TIL-based Therapies): Funding and Investments
Figure 2.20 Executive Summary (TIL-based Therapies): Patent Analysis
Figure 2.21 Executive Summary (TIL-based Therapies): Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Roadblocks
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigens
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 TCR-based Therapies: Distribution by Type of Developer
Figure 5.2 TCR-based Therapies: Distribution by Phase of Development
Figure 5.3 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 5.5 TCR-based Therapies: Distribution by Key Target Indication
Figure 5.6 TCR-based Therapies: Distribution by Key Target Antigen
Figure 5.7 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.8 TCR-based Therapies: Distribution by Route of Administration
Figure 5.9 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Figure 5.10 TCR-based Therapies: Distribution by Dosing Frequency
Figure 5.11 TCR-based Therapies: Distribution by Target Patient Segment
Figure 5.12 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.13 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Figure 5.14 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.15 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.16 TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 5.17 TCR-based Therapy Developers: Distribution by Company Size
Figure 5.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.19 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 TIL-based Therapies: Distribution by Type of Developer
Figure 6.2 TIL-based Therapies: Distribution by Phase of Development
Figure 6.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 6.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 6.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 6.6 TIL-based Therapies: Distribution by Route of Administration
Figure 6.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 6.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 6.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 6.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 6.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 6.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 TCR-based Therapies: Popular Targets in Hematological Malignancies
Figure 7.3 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.4 TCR-based Therapies: Popular Targets in Solid Tumors
Figure 7.5 CAR-Construction: Distribution by Generation of CAR
Figure 7.6 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.7 CAR-Construction: Distribution by Type of Virus Used
Figure 7.8 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.9 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Figure 8.3 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.4 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.6 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.9 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.13 CAR-T Cell Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.14 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.15 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.16 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.17 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.18 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.19 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.20 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.21 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 8.22 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.23 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.24 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.25 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.26 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.27 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.28 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.29 TCR-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.30 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.31 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.32 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.33 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.34 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.35 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Figure 8.36 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.37 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.38 TIL-based Therapies Clinical Trial Analysis: Distribution o by Trial Phase
Figure 8.39 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.40 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.41 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.42 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.43 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.44 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.45 TIL-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.46 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.47 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.48 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.49 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 9.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 9.4 CAR-T Cell Therapies: Distribution by Geographical Location of KOLs
Figure 9.5 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.8 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.10 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.11 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.12 TCR-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.13 TCR-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.14 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.15 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.16 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.17 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.18 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.19 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.20 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.21 TIL-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.22 TIL-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.23 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.24 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.25 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.26 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.27 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 10.1 Kymriah®: Estimated Sales Revenues
Figure 10.2 Yescarta®: Estimated Sales Revenues
Figure 10.3 Tecartus™: Estimated Sales Revenues
Figure 10.4 Breyanzi®: Estimated Sales Revenues
Figure 10.5 Abecma®: Estimated Sales Revenues
Figure 10.6 Carvykti®: Estimated Sales Revenues
Figure 10.7 Carteyva: Estimated Sales Revenues
Figure 10.8 TBI-1501: Estimated Sales Revenues
Figure 10.9 AUTO1: Estimated Sales Revenues
Figure 10.10 AUTO3: Estimated Sales Revenues
Figure 11.1 Kimmtrak®: Estimated Sales Revenues
Figure 11.2 GSK3377794: Estimated Sales Revenues
Figure 11.3 ADP-A2M4: Estimated Sales Revenues
Figure 11.4 JTCR016: Estimated Sales Revenues
Figure 11.5 TBI-1301: Estimated Sales Revenues
Figure 11.6 MDG1011: Estimated Sales Revenues
Figure 12.1 LN-144: Estimated Sales Revenues
Figure 12.2 LN-145: Estimated Sales Revenues
Figure 12.3 ITIL-168: Estimated Sales Revenues
Figure 12.4 LTX-315: Estimated Sales Revenues
Figure 13.1 Genome Editing Technologies: Applications
Figure 13.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 13.3 TALENS: Mechanism of Action
Figure 13.4 MegaTAL: Mechanism of Action
Figure 13.5 Zinc Finger Nuclease: Mechanism of Action
Figure 13.6 Competitiveness Analysis: Gene Editing Platforms
Figure 13.7 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 13.8 Cellectis: Properties of Enhanced T-Cell Platform
Figure 13.9 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 14.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.8 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Figure 14.9 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Figure 14.10 Most Popular Products: Distribution by Number of Partnerships
Figure 14.11 Most Active Industry Players: Distribution by Number of Partnerships
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 14.13 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 14.14 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 15.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 15.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 15.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 15.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 15.5 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 - 2022 (USD Million)
Figure 15.6 Funding and Investments: Distribution by Types of Investors
Figure 15.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 15.8 Most Active Players: Distribution by Number of Instances
Figure 15.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 15.10 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 15.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.3 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.4 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.5 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.6 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 16.7 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Figure 16.8 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Figure 16.9 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.10 CAR-T Cell Therapies Patent Analysis: Key Focus Area
Figure 16.11 Leading Industry Players: Distribution by Number of Patents
Figure 16.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 16.15 Patent Analysis: Distribution by Patent Age
Figure 16.14 CAR-T Therapies: Patent Valuation Analysis
Figure 16.15 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.16 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.17 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.18 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.19 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.20 TCR-based Therapies Patent Analysis: Distribution by Geography
Figure 16.21 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.22 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.23 TCR-based Therapies Patent Analysis: Key Focus Area
Figure 16.24 Leading Industry Players: Distribution by Number of Patents
Figure 16.25 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.26 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.27 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.28 Patent Analysis: Distribution by Patent Age
Figure 16.29 TCR-based Therapies: Patent Valuation Analysis
Figure 16.30 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.31 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.32 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.33 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.34 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.35 TIL-based Therapies Patent Analysis: Distribution by Geography
Figure 16.36 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.37 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.38 TIL-based Therapies Patent Analysis: Key Focus Area
Figure 16.39 Leading Industry Players: Distribution by Number of Patents
Figure 16.40 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.41 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.42 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.43 Patent Analysis: Distribution by Patent Age
Figure 16.44 TIL-based Therapies: Patent Valuation Analysis
Figure 17.1 Mechanism of Action of Gamma Delta T-Cells
Figure 17.2 Mechanism of Action of PD-1 Knockout Engineered T-Cell Therapies
Figure 17.3 Functions of Treg Cells
Figure 17.4 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Figure 17.7 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 17.5 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 17.6 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 18.1 Steps for Manufacturing Cell Therapies
Figure 18.2 Centralized Manufacturing: Process Model
Figure 18.3 Decentralized Manufacturing: Process Model
Figure 18.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 18.5 Cell Therapy: Challenges and Drivers
Figure 18.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 18.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 18.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 19.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 20.1 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Figure 20.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Figure 20.3 T-Cell Immunotherapy Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.4 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.5 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.7 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 20.8 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.9 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.10 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.11 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.12 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 20.13 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.14 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.15 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.16 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 20.17 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.18 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.19 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.22 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.23 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 20.24 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 20.25 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.26 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 20.27 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.28 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.29 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.30 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.31 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.32 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.33 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 20.34 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 20.35 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 20.36 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.37 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.38 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.39 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.40 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 20.41 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.42 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.43 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.44 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.45 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.46 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.47 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.48 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.49 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Figure 20.50 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.51 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.52 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.53 TCR-Based Therapies Market: Distribution by Target Antigen , 2025 and 2035 (USD Billion)
Figure 20.54 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.55 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.56 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 20.57 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 20.58 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 20.59 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.60 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.61 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.62 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.63 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.64 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.65 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.66 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.67 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Figure 20.68 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.69 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.70 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.71 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.72 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.73 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 20.74 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.75 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.76 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.77 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 21.1 Channels Used for Promotional Campaigns
Figure 21.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 21.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 21.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 21.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 21.6 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 21.7 Product Website Analysis: Yescarta®, Messages for Patients
Figure 21.8 Product Website Analysis: Yescarta®, Kite Konnect
Figure 21.9 Product Website Analysis: Yescarta®, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 21.10 Product Website Analysis: Tecartus™, Messages for Healthcare Professionals
Figure 21.11 Product Website Analysis: Tecartus™, Messages for Patients
Figure 21.12 Product Website Analysis: Tecartus™, Kite Konnect
Figure 21.13 Product Website Analysis: Breyanzi®, Messages for Healthcare Professional
Figure 21.14 Product Website Analysis: Breyanzi®, Messages for Patients
Figure 21.15 Product Website Analysis: Breyanzi®, Cell Therapy 360
Figure 21.16 Product Website Analysis: Abecma®, Messages for Healthcare Professional
Figure 21.17 Product Website Analysis: Abecma®, Messages for Patients
Figure 21.18 Product Website Analysis: Abecma®, Cell Therapy 360
Figure 21.19 Product Website Analysis: Carvykti®, Messages for Healthcare Professional
Figure 21.20 Product Website Analysis: Carvykti®, Messages for Patients
Figure 21.21 Product Website Analysis: Carvykti®, MyCARVYKTI
Figure 21.22 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 21.23 Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 21.24 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Key Opinion Leaders
Figure 23.4 Concluding Remarks: Partnerships and Collaborations
Figure 23.5 Concluding Remarks: Funding and Investments Analysis
Figure 23.6 Concluding Remarks: Patent Analysis
Figure 23.7 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9 CAR-T Cell and TCR-based Therapies: Key Differences
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 TCR-based Therapies: Clinical Pipeline
Table 5.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 5.3 TCR-based Therapies: Preclinical Pipeline
Table 5.4 List of TCR-based Developers,
Table 6.1 TIL-based Therapies: Clinical Pipeline
Table 6.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 6.3 TIL-based Therapies: Preclinical Pipeline
Table 6.4 List of TIL-based Developers
Table 7.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 10.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 10.2 Therapy Profile: Kymriah® (Novartis)
Table 10.3 Kymriah®: Clinical Trial Information
Table 10.4 Kymriah®: Clinical Trial Endpoints
Table 10.5 Kymriah®: Clinical Trial Results
Table 10.6 Therapy Profile: Yescarta® (Gilead Sciences)
Table 10.7 Yescarta®: Clinical Trial Information
Table 10.8 Yescarta®: Clinical Trial Endpoints
Table 10.9 Yescarta®: Clinical Trial Results
Table 10.10 Therapy Profile: Tecartus™ (Gilead Sciences)
Table 10.11 Tecartus™: Clinical Trial Information
Table 10.12 Tecartus™: Clinical Trial Endpoints
Table 10.13 Tecartus™: Clinical Trial Results
Table 10.14 Therapy Profile: Breyanzi® (Bristol Myers Squibb)
Table 10.15 Breyanzi®: Clinical Trial Information
Table 10.16 Breyanzi®: Clinical Trial Endpoints
Table 10.17 Breyanzi®: Clinical Trial Results
Table 10.18 Therapy Profile: Abecma® (Bristol Myers Squibb)
Table 10.19 Abecma®: Clinical Trial Information
Table 10.20 Abecma®: Clinical Trial Endpoints
Table 10.21 Abecma®: Clinical Trial Results
Table 10.22 Therapy Profile: Carvykti™ (Janssen)
Table 10.23 Carvykti™: Clinical Trial Information
Table 10.24 Carvykti™: Clinical Trial Endpoints
Table 10.25 Carvykti™: Clinical Trial Results
Table 10.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 10.27 Carteyva: Clinical Trial Information
Table 10.28 Carteyva: Clinical Trial Endpoints
Table 10.29 Carteyva: Clinical Trial Results
Table 10.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 10.31 TBI-1501: Clinical Trial Information
Table 10.32 TBI-1501: Clinical Trial Endpoints
Table 10.33 Therapy Profile: AUTO1 (Autolus)
Table 10.34 AUTO1: Clinical Trial Information
Table 10.35 AUTO1: Clinical Trial Endpoints
Table 10.36 AUTO1: Clinical Trial Results
Table 10.37 Therapy Profile: AUTO3 (Autolus)
Table 10.38 AUTO3: Clinical Trial Information
Table 10.39 AUTO3: Clinical Trial Endpoints
Table 10.40 AUTO3: Clinical Trial Results
Table 11.1 TCR Cell Therapies: List of Therapies Profiled
Table 11.2 Therapy Profile: Kimmtrak (Immunocore)
Table 11.3 Kimmtrak: Clinical Trial Information
Table 11.4 Kimmtrak: Clinical Trial Endpoints
Table 11.5 Kimmtrak: Clinical Trial Results
Table 11.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 11.7 GSK3377794: Clinical Trial Information
Table 11.8 GSK3377794: Clinical Trial Endpoints
Table 11.9 GSK3377794: Clinical Trial Results
Table 11.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 11.11 ADP-A2M4: Clinical Trial Information
Table 11.12 ADP-A2M4: Clinical Trial Endpoints
Table 11.13 ADP-A2M4: Clinical Trial Results
Table 11.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 11.15 JTCR016: Clinical Trial Information
Table 11.16 JTCR016: Clinical Trial Endpoints
Table 11.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 11.18 TBI-1301: Clinical Trial Information
Table 11.19 TBI-1301: Clinical Trial Endpoints
Table 11.20 TBI-1301: Clinical Trial Results
Table 11.21 Therapy Profile: MDG1011 (Medigene)
Table 11.22 MDG1011: Clinical Trial Information
Table 11.23 MDG1011: Clinical Trial Endpoints
Table 11.24 MDG1011: Clinical Trial Results
Table 12.1 TIL Cell Therapies: List of Therapies Profiled
Table 12.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 12.3 LN-144: Clinical Trial Information
Table 12.4 LN-144: Clinical Trial Endpoints
Table 12.5 LN-144: Clinical Trial Results
Table 12.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 12.7 LN-145: Clinical Trial Information
Table 12.8 LN-145: Clinical Trial Endpoints
Table 12.9 LN-145: Clinical Trial Results
Table 12.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 12.11 ITIL-168: Clinical Trial Information
Table 12.12 ITIL-168: Clinical Trial Endpoints
Table 12.13 ITIL-168: Clinical Trial Results
Table 12.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 12.15 LTX-315: Clinical Trial Information
Table 12.16 LTX-315: Clinical Trial Endpoints
Table 12.17 LTX-315: Clinical Trial Results
Table 13.1 Bellicum Pharmaceuticals: Key Switch Technologies
Table 13.2 Technologies For CAR-T Safety Enhancement
Table 14.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2022
Table 15.1 T-Cell Immunotherapies: Funding and Investments, 2000-2022
Table 15.2 T-Cell Immunotherapies: Summary of Investments
Table 16.1 CART-Cell Therapy Patent Analysis: Prominent CPC Symbols
Table 16.2 CART-Cell Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.3 CART-Cell Therapy Patent Analysis: List of Top CPC Symbols
Table 16.4 CART-Cell Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.5 CART-Cell Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.6 TCR-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.7 TCR-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.8 TCR-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.9 TCR-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.10 TCR-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.11 TIL-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.12 TIL-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.13 TIL-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.14 TIL-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.15 TIL-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.1 Characteristic Properties of Treg Cells
Table 17.2 Other T-Cell Immunotherapies: Therapy Candidate Pipeline
Table 18.1 Assessment Strategies for Different Manufacturing Processes
Table 18.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 18.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 19.1 Price of Marketed Gene / Cell Therapies
Table 19.2 Price of Marketed Targeted Drugs
Table 19.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 19.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 20.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 20.2 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Net Present Value (USD Million)
Table 20.3 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Value Creation Analysis (USD Million)
Table 20.4 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Net Present Value (USD Million)
Table 20.5 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.6 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Net Present Value (USD Million)
Table 20.7 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.8 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.9 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.10 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Net Present Value (USD Million)
Table 20.11 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Value Creation Analysis (USD Million)
Table 20.12 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.13 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.14 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 20.15 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 20.16 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.17 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 20.21 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 20.22 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.23 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.24 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.25 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.26 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 20.27 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 20.28 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 20.29 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 20.30 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 20.31 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 20.32 TAK-007 (Takeda): Net Present Value (USD Million)
Table 20.33 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 20.34 AUTO1 (Autolus): Net Present Value (USD Million)
Table 20.35 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 20.36 AUTO3 (Autolus): Net Present Value (USD Million)
Table 20.37 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 20.38 CD19-CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 20.39 CD19-CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 20.40 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.41 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.42 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 20.43 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 20.44 CCT301 CAR-T (Shanghai PerHum Therapeutics): Net Present Value (USD Million)
Table 20.45 CCT301 CAR-T (Shanghai PerHum Therapeutics): Value Creation Analysis (USD Million)
Table 20.46 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 20.47 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 20.48 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 20.49 CARCIK-CD19 (CoImmune): Value Creation Analysis (USD Million)
Table 20.50 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 20.51 PBCAR269A (Precision BioSciences / Servier): Value Creation Analysis (USD Million)
Table 20.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.54 BCMA CAR-T (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.55 BCMA CAR-T (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.57 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.58 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 20.59 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 20.60 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 20.61 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 20.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.63 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.64 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 20.65 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 20.66 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.67 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.69 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.70 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 20.71 CT053 (CARsgen Therapeutics)): Value Creation Analysis (USD Million)
Table 20.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.73 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.75 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.76 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.77 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.78 WU CART 007 (Wugen): Net Present Value (USD Million)
Table 20.79 WU CART 007 (Wugen): Value Creation Analysis (USD Million)
Table 20.80 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 20.81 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.82 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 20.83 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 20.84 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 20.85 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 20.86 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 20.87 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 20.88 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 20.89 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 20.90 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.91 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.92 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 20.93 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 20.94 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 20.95 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 20.96 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 20.97 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 20.98 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.99 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.100 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.101 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.102 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.103 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.104 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 20.105 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 20.106 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 20.107 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 20.108 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 20.109 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 20.110 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 20.111 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 20.112 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.113 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.114 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 20.115 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 20.116 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 20.117 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 21.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 21.2 Kymriah®: Drug Overview
Table 21.3 Yescarta®: Drug Overview
Table 21.4 Tecartus™: Drug Overview
Table 21.5 Breyanzi®: Drug Overview
Table 21.6 Abecma®: Drug Overview
Table 21.7 Carvykti™: Drug Overview
Table 21.8 Kimmtrak®: Drug Overview
Table 22.1 Leading T-Cell Immunotherapy Developers
Table 22.2 Adaptimmune Therapeutics: Company Profile
Table 22.3 Alaunos Therapeutics: Company Profile
Table 22.4 Autolus: Company Profile
Table 22.5 bluebird bio: Company Profile
Table 22.6 Bristol Myers Squibb: Company Profile
Table 22.7 CARsgen Therapeutics: Company Profile
Table 22.8 Cellectis: Company Profile
Table 22.9 Cellular Biomedicine Group: Company Profile
Table 22.10 Gilead Sciences: Company Profile
Table 22.11 GlaxoSmith Kline: Company Profile
Table 22.12 Immatics: Company Profile
Table 22.13 Immunocore: Company Profile
Table 22.14 Innovative Cellular Therapeutics: Company Profile
Table 22.15 Iovance Biotherapeutics: Company Profile
Table 22.16 Kuur Therapeutics: Company Profile
Table 22.17 Lion TCR: Company Profile
Table 22.18 Noile-Immune Biotech: Company Profile
Table 22.19 Novartis: Company Profile
Table 22.20 Shanghai Genechem: Company Profile
Table 22.21 Sinobioway Cell Therapy: Company Profile
Table 22.22 Takara Bio: Company Profile
Table 22.23 Wellington Zhaotai Therapies: Company Profile
Table 22.24 Zelluna Immunotherapy: Company Profile
Table 25.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 25.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 25.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 25.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Table 25.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Table 25.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 25.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Table 25.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 25.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 25.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 25.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Table 25.19 TCR-based Therapies: Distribution by Type of Developer
Table 25.20 TCR-based Therapies: Distribution by Phase of Development
Table 25.21 TCR-based Therapies: Distribution by Therapeutic Area
Table 25.22 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.23 TCR-based Therapies: Distribution by Key Target Indication
Table 25.24 TCR-based Therapies: Distribution by Key Target Antigen
Table 25.25 TCR-based Therapies: Distribution by Source of T-Cells
Table 25.26 TCR-based Therapies: Distribution by Route of Administration
Table 25.27 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Table 25.28 TCR-based Therapies: Distribution by Dosing Frequency
Table 25.29 TCR-based Therapies: Distribution by Target Patient Segment
Table 25.30 TCR-based Therapies: Distribution by Type of Therapy
Table 25.31 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Table 25.32 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Table 25.33 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Table 25.34 TCR-based Therapy Developers: Distribution by Year of Establishment
Table 25.35 TCR-based Therapy Developers: Distribution by Company Size
Table 25.36 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.37 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.38 TIL-based Therapies: Distribution by Type of Developer
Table 25.39 TIL-based Therapies: Distribution by Phase of Development
Table 25.40 TIL-based Therapies: Distribution by Therapeutic Area
Table 25.41 TIL-based Therapies: Distribution by Key Target Indications
Table 25.42 TIL-based Therapies: Distribution by Source of T-Cells
Table 25.43 TIL-based Therapies: Distribution by Route of Administration
Table 25.44 TIL-based Therapies: Distribution by Dosing Frequency
Table 25.45 TIL-based Therapies: Distribution by Target Patient Segment
Table 25.46 TIL-based Therapies: Distribution by Type of Therapy
Table 25.47 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Table 25.48 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 25.49 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 25.50 TIL-based Therapy Developers: Distribution by Company Size
Table 25.51 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.52 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.53 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Table 25.54 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.55 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.56 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.57 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.58 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.59 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.60 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.61 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.62 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.63 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.64 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.65 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.66 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.67 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.68 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-20172022
Table 25.69 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.70 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.71 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Table 25.72 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.73 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.74 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.75 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.76 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.77 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.78 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.79 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.80 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.81 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.82 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.83 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Table 25.84 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Table 25.85 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.86 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.87 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.88 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.89 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.90 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.91 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.92 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.93 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.94 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.95 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.96 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.97 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.98 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 25.99 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.100 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 25.101 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.102 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.103 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.104 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.105 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.106 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.107 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.108 TCR-based Therapies KOL Analysis: Distribution by Qualification
Table 25.109 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.110 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.111 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.112 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.113 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.114 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.115 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.116 TIL-based Therapies KOL Analysis: Distribution by Qualification
Table 25.117 TIL-based Therapies: Geographical Distribution of KOLs
Table 25.118 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.119 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.120 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.121 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.122 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.123 Kymriah®: Estimated Sales Revenues
Table 25.124 Yescarta®: Estimated Sales Revenues
Table 25.125 Tecartus™: Estimated Sales Revenues
Table 25.126 Breyanzi®: Estimated Sales Revenues
Table 25.127 Abecma®: Estimated Sales Revenues
Table 25.128 Carvykti®: Estimated Sales Revenues
Table 25.129 Carteyva: Estimated Sales Revenues
Table 25.130 TBI-1501: Estimated Sales Revenues
Table 25.131 AUTO1: Estimated Sales Revenues
Table 25.132 AUTO3: Estimated Sales Revenues
Table 25.133 Kimmtrak®: Estimated Sales Revenues
Table 25.134 GSK3377794: Estimated Sales Revenues
Table 25.135 ADP-A2M4: Estimated Sales Revenues
Table 25.136 JTCR016: Estimated Sales Revenues
Table 25.137 TBI-1301: Estimated Sales Revenues
Table 25.138 MDG1011: Estimated Sales Revenues
Table 25.139 LN-144: Estimated Sales Revenues
Table 25.140 LN-145: Estimated Sales Revenues
Table 25.141 ITIL-168: Estimated Sales Revenues
Table 25.142 LTX-315: Estimated Sales Revenues
Table 25.143 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 25.144 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.145 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.146 Partnerships and Collaborations: Distribution by Type of Product
Table 25.147 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Therapy
Table 25.148 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 25.149 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.150 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.151 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Table 25.152 Most Popular Products: Distribution by Number of Partnerships
Table 25.153 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.154 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.155 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 25.156 Partnerships and Collaborations: Distribution of International and Local Deals
Table 25.157 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 25.158 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 25.159 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 25.160 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.161 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 - 2022 (USD Million)
Table 25.162 Funding and Investments: Distribution by Types of Investors
Table 25.163 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 25.164 Most Active Players: Distribution by Number of Instances
Table 25.165 Most Active Players: Distribution by Amount Invested
Table 25.166 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 25.167 Most Active Investors: Distribution by Number of Funding Instances
Table 25.168 Patent Analysis: Distribution by Type of Patent
Table 25.169 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.170 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.171 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.172 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.173 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 25.174 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 25.175 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 25.176 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.177 Leading Industry Players: Distribution by Number of Patents
Table 25.178 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.179 Leading Patent Assignees: Distribution by Number of Patents
Table 25.180 Patent Analysis: Distribution by Patent Age
Table 25.181 CAR-T Therapies: Patent Valuation Analysis
Table 25.182 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.183 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.184 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.185 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.186 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Table 25.187 TCR-based Therapies Patent Analysis: Distribution by Geography
Table 25.188 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.189 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.190 Leading Industry Players: Distribution by Number of Patents
Table 25.191 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.192 Leading Patent Assignees: Distribution by Number of Patents
Table 25.193 Patent Analysis: Distribution by Patent Age
Table 25.194 TCR-based Therapies: Patent Valuation Analysis
Table 25.195 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.196 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.197 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.198 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.199 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted patents
Table 25.200 TIL-based Therapies Patent Analysis: Distribution by Geography
Table 25.201 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.202 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.203 Leading Industry Players: Distribution by Number of Patents
Table 25.204 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.205 Leading Patent Assignees: Distribution by Number of Patents
Table 25.206 Patent Analysis: Distribution by Patent Age
Table 25.207 TIL-based Therapies: Patent Valuation Analysis
Table 25.208 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Table 25.209 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 25.210 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 25.211 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 25.212 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Table 25.213 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Table 25.214 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Table 25.215 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035
Table 25.216 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.217 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.218 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Table 25.219 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.220 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.221 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.222 CAR-T Cell Therapies Market: Distribution by Target Geography, 2025 and 2035 (USD Billion)
Table 25.223 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Table 25.224 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.225 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.226 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.227 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Table 25.228 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.229 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.230 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.231 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Table 25.232 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.233 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.234 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Table 25.235 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Table 25.236 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.237 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Table 25.238 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.239 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.240 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.241 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.242 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast till 2035 (USD Million)
Table 25.243 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.244 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Table 25.245 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Table 25.246 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Table 25.247 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.248 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.249 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.250 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.251 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Table 25.252 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.253 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.254 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.255 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.256 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.257 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.258 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.259 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.260 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Table 25.261 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.262 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Table 25.263 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.264 TCR-Based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.265 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.266 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.267 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales
Table 25.268 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Table 25.269 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Table 25.270 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.271 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.272 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.273 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Table 25.274 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, 2035 (USD Million)
Table 25.275 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.276 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Table 25.277 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.278 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Table 25.279 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.280 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.281 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.282 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.283 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.284 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Table 25.285 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Table 25.286 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.287 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.288 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

2seventy bio
3E Bioventures Capital
5AM Ventures
6 Dimensions Capital
8VC
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Academy of Military Medical Sciences
AbbVie Ventures
AbCellera
AbCheck
AbClon
Abingworth
Abound Bio
AbVitro
Abzena
Atunizade
Ac?badem Labcell
Acibadem University
Acorn Bioventures
ACROBiosystems
Actinium Pharmaceuticals
Adage Capital Management
AdAlta
Adaptimmune Therapeutics
Adicet Bio
Adimab
Affiliated Hospital of Jiangnan University
Affiliated Hospital of Jiangsu University
Affiliated Hospital to Academy of Military Medical Sciences
Affiliated Zhongshan Hospital of Dalian University
AffyImmune Therapeutics
AGC Biologics
Agency for Science, Technology and Research (A*STAR)
Agent Capital
AgonOx
Agreen Biotech
Aisling Capital
AK (Suzhou) Biomedical
Alaunos Therapeutics
Aleta Biotherapeutics
Alex’s Lemonade Stand Foundation
Alexandria Venture Investments
Alpha Wave Global (Formerly known as Falcon Edge Capital)
Allife Medical Science and Technology
Allogene Therapeutics
Alpha Biopharma
Alpine Immune Sciences
ALSHC
Americo
Amgen Ventures
Andera Partners
Anhui Anke Biotechnology
Anhui Provincial Hospital
Anocca
Antion Biosciences
Apeiron Investment Group
Appia Bio
Applied DNA Sciences
Aquilo Capital Management
ARBELE
Arbor Biotechnologies
Arcellx
ARCH Venture Partners
Arix Bioscience
ArrowMark Partners
Astellas Pharma
Astellas Venture Management
Astero Bio
AstraZeneca
Asymmetry Asset Management
Asymptote
Atara Biotherapeutics
ATEM Capital
Athenex
Atlas Venture
August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
Aurora Biopharma
Autolus
Avego BioScience Capital
AvenCell
AVICT Global
Avidity Partners
B Capital Group
Bambino Gesù Hospital and Research Institute
Bayer
Baylor College of Medicine
Be The Match BioTherapies
Beam Therapeutics
Beijing 302 Hospital
Beijing Biohealthcare Biotechnology
Beijing Boren Hospital
Beijing Cancer Hospital
Beijing Chaoyang Hospital
Beijing Children's Hospital
Beijing Doing Biomedical
Beijing GoBroad Hospital Management
Beijing HuiNengAn Biotech
Beijing Immunochina Medical Science & Technology
Beijing Lu Daopei Hospital
Beijing Mario Biotech
Beijing Sanbo Brain Hospital
Beijing Tsinghua Chang Gung Hospital
Beike Biotechnology
Bellicum Pharmaceuticals
Berlin Institute of Health
Bessemer Venture Partners
Beth Israel Deaconess Medical Center (BIDMC)
BiGEN
BINEX
Bioceltech Therapeutics
BioCopy
Bio-Gene Technology
BioLife Solutions
Bionomics
BioNTech
Bioray Laboratories
Biosceptre
BlackRock
Blackstone Life Sciences
Blood Centers of America
bluebird bio
BlueRun Ventures
Boxer Capital
Boya Jiyin
BoYuan RunSheng Pharma (Hangzhou)
Brace Pharma Capital
Brigham & Women’s Hospital
Bristol-Myers Squibb
British Patient Capital
Broad Institute
Bukwang Pharmaceutical
BVCF Management
CaaS Capital Management
Cabaletta Bio
Cabaret Biotech
Calibr
California Institute for Regenerative Medicine (CIRM)
California Institute of Technology
CAM Capital
Cambrian Biopharma
Canaan Partners
Cancer Prevention Research Institute of Texas
Cancer Research Technology
Cancer Research UK
Carbiogene Therapeutics
Cardiff University
Caribou Biosciences
Carina Biotech
Caring Cross
CARISMA Therapeutics
CARsgen Therapeutics
CAR-T (Shanghai) Cell Biotechnology
Cartesian Therapeutics
Cartherics
Casdin Capital
Case Comprehensive Cancer Center
Casebia Therapeutics
Catalio Capital Management
CCB International
CDH Investments
Celdara Medical
Celgene
Cell and Gene Therapy Catapult
Cell Design Labs
Cellares
Cellectis
Cellex Patient Treatment
CELLforCURE
CellPoint
Cellular Biomedicine Group
Cellular Therapeutics
CellVec
Celularity
Celyad Oncology
Center for International Blood and Marrow Transplant Research
Central South University
Changhai Hospital
Charité - Universitätsmedizin Berlin
Chengdu International Bio-Town Investment and Development
Chengdu USino Technology Biology
Children’s Hospital of Philadelphia
Children's Hospital Foundation
Children's Hospital of Fudan University
Children's Hospital of Philadelphia
China Everbright
China Immunotech (Beijing) Biotechnology
China Meitan General Hospital
China Regenerative Medicine International (CRMI)
China Resources Innovative Equity Investment Fund
China (Nanjing) Cell Valley
Chinese Academy of Sciences
Chinese PLA General Hospital
Chongqing Precision Biotech
Chongqing Public Health Medical Center
Chongqing Sidemu Biotechnology Technology
Chongqing University Cancer Hospital
CICC
City of Hope National Medical Center
Clough Capital
CMG-SDIC Capital
CNCB Capital
Cognate BioServices
CoImmune
Cold Spring Harbor Laboratory
Columbia University
Column Group Crossover Fund
Cormorant Asset Management
Corregene Biotechnology
CoStone Capital
Cowen
Co-win Ventures
CPE Capital
CR-CP Life Science Fund
CRISPR Therapeutics
Cryoport
CTM CRC
Curative Ventures
CureSearch for Children's Cancer
Curocell
CytoLumina Technologies
CytoMed Therapeutics
Cytovant Sciences
Cytovia Therapeutics
Dai-ichi Life
Daiichi Sankyo
Dalton Capital
Dalton Venture
Dana-Farber Cancer Institute
Danske Bank
Dartmouth College
Daxie Pengchuang Investment
Decheng Capital
Deep Track Capital
Deerfield Management
Deguan Capital
Delenex Therapeutics
Delian Capital
Direct Selling Association of Malaysia (DSAM)
Ditch Plains Capital Management
German Aerospace Center (DLR)
Dongguan People's Hospital
Droia Ventures
DS Asset Management
Duke Management Company
Duke-NUS Medical School
Dutch Cancer Society
Earle A. Chiles Research Institute
EcoR1 Capital
Eden BioCell
Editas Medicine
Efung Capital
Ehime University
Eli Lilly
Elicera Therapeutics
Elikon Venture
Elpis Biopharmaceuticals
Emerson Collective
Epidarex Capital
EQT Life Sciences
Erasmus MC
Etcembly
Eureka Therapeutics
European Commission
Eutilex
Eventide Asset Management
EXUMA Biotech
Farallon Capital Management
Fate Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
FetoLumina Technologies
Fidelity Biosciences
Fidelity Management & Research
Fidim
First Affiliated Hospital of Chengdu Medical College
First Affiliated Hospital of Harbin Medical University
First Affiliated Hospital of Jinan University
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital, Sun Yat-sen University
First Hospital of Jilin University
First People's Hospital of Foshan
First People's Hospital of Changzhou
Five Prime Therapeutics
Fiverings
Flagship Ventures
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
European Social Fund
Fondos ARI (Assistencia Recerca Intensiva)
Foresite Capital
Fortress Biotech (Formerly known as Coronado Biosciences)
Formula Pharmaceuticals
Fortress Investment
Fosun Pharmaceutical
Fourth Hospital of Hebei Medical University
F-Prime
Franklin Templeton
Fraunhofer
Fred Hutchinson Cancer Research Center
Fudan University
Fujian Medical University
Fujifilm
Fujita Health University
Fundamenta Therapeutics
Future Ventures
FutureGen Biopharm
G.N. Tech Venture
Gadeta
GC LabCell
GE Global Research
GE Healthcare
Gene Therapy Center
Genentech
Genezen
Genmab
Genocea Biosciences
Genome Institute of Singapore
Genus Oncology
Gencells Therapeutics
GIC
GigaGen
Gilead Sciences
GL Ventures
GlaxoSmithKline
Glycostem Therapeutics
GlyTherix
Google Ventures
Gracell Biotechnologies
Great Ormond Street Hospital for Children NHS Foundation Trust
Green Cross Holdings
Gritstone Oncology
Guangdong Chongye Holdings
Guangdong General Hospital
Guangdong Xiangxue Precision Medical Technology
Guangdong Zhaotai InVivo Biomedicine
Guangzhou Eighth People's Hospital
Guangzhou Anjie Biomedical Technology
Guangzhou FineImmune Biotechnology
Guangzhou First People's Hospital
Guangzhou Institute of Respiratory Disease
GV
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H.C. Wainwright & Co.
Hadassah Medical Organization
Haitong International Securities
Harvard University
HCW Biologics
Hebei Senlang Biotechnology
Hebei Yanda Ludaopei Hospital
Hefei Binhu Hospital
Heidelberg University Hospital
Helmholtz Zentrum München
Henan Cancer Hospital
Henan Hualong Biotechnology
Henan Provincial People's Hospital
Hengzhen Investment
Heritage Medical Systems
Herlev Hospital
HiFiBiO Therapeutics
Hillhouse Capital
Hitachi Chemical Advanced Therapeutics Solutions
Horizon 2020
Horizon Discovery
Horizon Technology Finance
Houston Methodist Hospital
Howard Hughes Medical Institute
Hrain Biotechnology
HuaDao (Shanghai) Biomedical
Huazhong University of Science and Technology
Hudson Bay Capital Management
Hunan Provincial People's Hospital
Hunan Yongren Medical Innovation
Hunan Zhaotai Yongren Biotech
Hunan Zhaotai Yongren Medical Innovation
Huzhou Jiuli Industrial Investment
IASO Biotherapeutics
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ICON
IIT MediTech (Jiangsu)
Immatics
Immatics Biotechnologies
Immetacyte
ImmunoACT
Immunocore
Immunotech Biopharm
Immunotherapy Foundation
Imperial Innovations
Imugene
Incyte
Inhibrx
Innovative Cellular Therapeutics
Innovent Biologics
Instil Bio
Institut Curie
Institute of Hematology & Blood Diseases Hospital
Institute of Hematology and Blood Transfusion
Instituto de Salud Carlos III
Intellia Therapeutics
Intermediate Capital (ICG)
Intima Bioscience
Intrexon
Invectys
Invesco Perpetual
Invus
Iovance Biotherapeutics
IRICoR
Janssen
Janus Capital Group
Janus Henderson Investors
Jebsen Capital
Jeito Capital
Jiadao Fanghua
Jiadao Private Capital
Jiangsu Huarui Investment Management
Jiangsu Province Hospital of Traditional Chinese Medicine
Jiangyin People's Hospital
Jiaxing Industrial Investment
Jichi Medical University Hospital
Jingjiang People's Hospital
Jingzhou Central Hospital
JM Family
Johnson & Johnson Innovation
Jonsson Comprehensive Cancer Center
Junchenda Capital
Juno Therapeutics
Juventas Cell Therapy
JW Therapeutics
KAEDI
Kaixin Bio
Kangyu Capital
Kangyuan Huiying
Karolinska Institute
KBI Biopharma
Kecellitics Biotech
Key Biologics
Khosla Ventures
King Star Med
King's College London
Kite Pharma
Kolon Investment
Korea SMEs & Startups Agency
KSQ Therapeutics
Kuur Therapeutics
Kyverna Therapeutics
Laurion Capital Management
Legend Biotech
Leiden University Medical Center
Leucid Bio
Leukemia & Lymphoma Society
Leukemia Research Foundation
Level One Partners
LG Tech
Life Technologies
LifeSci Venture Partners
Lightchain Capital
Lightstone Ventures
Lilly Asia Ventures
Liminatus Pharma
Lincoln Park Capital Fund
Lion TCR
Living Pharma
Logos Capital
Longevity Fund
Longitude Capital
Longmen Capital
Longwood Fund
Lonza
Loyal Valley Capital
Loyola University Medical Center
Lucion Group
Ludwig Cancer Research
LUMICKS
LVC Super Unicorn Fund
Lyell Immunopharma
Lytix Biopharma
LYZZ Capital
M.D. Anderson Cancer Center
MabQuest
Malaghan Institute of Medical Research
Malin
Marino Biotechnology
Marker Therapeutics
Massachusetts General Hospital
Massachusetts Institute of Technology
MaSTherCell
Matrix Capital Management
Matrix Partners China
Maverick Ventures
Max Delbrück Center for Molecular Medicine
MaxCyte
Mayo Clinic
MD Anderson Cancer Center
Medical College of Wisconsin
Medigene
MedImmune
Medisix Therapeutics
MediTrust Health
Medivate Partners
Memorial Sloan Kettering Cancer Center
Merck
Merlin Nexus
Mie University Hospital
Miller Value Partners
Miltenyi Biomedicine
Miltenyi Biotec
Minderoo Foundation
Minerva Biotechnologies
MiNK Therapeutics
Mirae Asset Financial Group
Moderna
MolMed (Acquired by AGC Biologics)
Monashee Investment Management
Moore Strategic Ventures
Morningside Ventures
MSD Partners
Mustang Bio
Myst Therapeutics
Nagoya University
Nanfang Hospital of Southern Medical University
Nanjing Bioheng Biotech
Nanjing Drum Tower Hospital
Nanjing Children's Hospital
NantKwest
Nantong University
NantWorks
National Cancer Center Hospital East
National Cancer Center Japan
National Cancer Institute
National Education Association
National Heart, Lung and Blood Institute
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
National Institutes of Health (NIH)
National Institutes of Health Clinical Center
National Taiwan University Hospital
National University Hospital
Navy General Hospital
Neogene Therapeutics
NeoSTEM
New Enterprise Associates
New Leaf Venture Partners
New York State Stem Cell Science Program (NYSTEM)
Nextech Invest
NIH Small Business Innovation Research (SBIR)
Ningbo Cancer Hospital
Nipro
Nkarta
Noile-Immune Biotech
Northern Jiangsu People's Hospital
Northern Light Venture Capital
Northleaf Capital Partners
Northpond Ventures
Notch Therapeutics
Novartis
Novartis Venture Fund
Novo Nordisk
nSAGE
NSF Engineering Research Center for Cell Manufacturing Technologies
NSR Financial
Nurix Therapeutics
Oaktree Capital Management
Oceanpine Capital
Octagon Capital
OCV Partners
Omega Funds
Oncodesign Biotechnology
Oncora Medical
OncoTracker
Oncternal Therapeutics
OnCyte
ONK Therapeutics
oNKo-innate
Ono Pharmaceutical
Opus Bio
OriginCell Therapeutics
OrbiMed Advisors
ORI Capital
Oriza
Oriza Seed Venture Capital
Osage University Partners
Oslo University Hospital
Ospedale Pediatrico Bambino Gesù (OPBG)
Otsuka Pharmaceutical
Ottawa Hospital Research Institute
Outpace Bio
Overland Pharmaceuticals
Oxford BioMedica
Oxford BioTherapeutics
Oxford MEStar
PACT Pharma
Panacea Ventures
PanCELLa
Parker Institute for Cancer Immunotherapy
Partners Innovation Fund
Pediatric Brain Tumor Consortium
Peking Union Medical College Hospital
Peking University People's Hospital
Peking University Shenzhen Hospital
Peking University Third Hospital
Pentwater Capital Management
PeproMene Bio
Perceptive Advisors
Perceptive Bioscience Investments
PersonGen BioTherapeutics
Peter MacCallum Cancer Centre
Pfenex
Pfizer
PFM Health Sciences
PharmaCell
PharmaEssentia
Pharmalog
Phio Pharmaceuticals
PhoreMost
Pieris Pharmaceuticals
Pierre Fabre
Pinze Lifetechnology
Pitango Venture Capital
Pivotal bioVenture Partners
Plaisance Capital
Platinum Asset Management
Point72
Polaris Partners
PolyBioCept
Pontifax
Posco Capital
Poseida Therapeutics
Precigen
Precision BioSciences
Pregenen (Acquired by bluebird bio)
Presight Capital
Progenitor Cell Therapy
ProMab Biotechnologies
Prometheus Capital
Prometheus Laboratories
Protheragen
Providence Cancer Institute of Oregon
Providence Health & Services
Pura Vida Investments
Qatar Investment Authority (QIA)
QIAGEN
Qian Hai Wan Hui Equity Investment Fund Management (Shenzhen)
Qilu Hospital of Shandong University
Qingzhe Capital
QVT Financial
RA Capital Management
Red Hill Capital
Redmile Group
RedoxTherapeis
Refuge Biotechnologies
Regeneron Pharmaceuticals
Renji Hospital
Resilience
resTORbio
RFund
Ridgeback Capital Investments
Ridgeback Capital Management
RiverVest
RM Global Partners
Roche
Rock Spring Capital
Rockland Immunochemicals
Roger Williams Medical Center
Rosewell Park Comprehensive Cancer Center
Royal Adelaide Hospital Cancer Centre
RTW Investments
Ruijin Hospital
Ruisheng Investment
Rutgers University
Russian Direct Investment Fund
RXi Pharmaceuticals
Sabby Management
Sabz Biomedicals
Samsara BioCapital
Sana Biotechnology
Sands Capital
Sangamo Therapeutics
Sanofi
Sanofi-Genzyme BioVentures
Schonfeld Strategic Advisors
SciLifeLab
Scotia Biologics
Seattle Children’s Research Institute
Seattle Children's Hospital
Seattle Children's Research Institute
Seattle Genetics
Seattle Cancer Care Alliance
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Nanchang University
Second Affiliated Hospital of Soochow University
Second Affiliated Hospital of Xi'an Jiaotong University
Second People’s Hospital of Huai’an
Second Military Medical University
Second Xiangya Hospital of Central South University
Sectoral Asset Management
Selexis
Sequoia Capital China
Servier
Shanghai Cancer Institute
Shanghai Biomed-Union Biotechnology
Shanghai Bioray Laboratory
Shanghai Cell Therapy
Shanghai Changzheng Hospital
Shanghai Chest Hospital
Shanghai Children's Medical Center
Shanghai East Hospital
Shanghai GeneChem
Shanghai General Hospital
Shanghai International Medical Center
Shanghai Jiao Tong University School of Medicine
Shanghai Longyao Biotechnology
Shanghai Ming Ju Biotechnology
Shanghai PerHum Therapeutics
Shanghai Pharmaceuticals
Shanghai Public Health Clinical Center
Shanghai Pudong Science & Technology Investment
Simnova Biotherapeutics
Shanghai Sixth People's Hospital
Shanghai Tongren Hospital
Shanghai Tongji Hospital
Shanghai Ultra-T Immune Therapeutics
Shanghai Unicar-Therapy Bio-medicine Technology
Shanghai Zhongshan Hospital
Shanxi Province Cancer Hospital
Shariati Hospital
Sheba Medical Center
Shenzhen Binde Biotechnology
Shenzhen BinDeBio
Shenzhen Capital Group
Shenzhen Children's Hospital
Shenzhen Geno-immune Medical Institute
Shenzhen Hospital of Southern Medical University
Shenzhen Institute for Innovation and Translational Medicine
Shenzhen Second People's Hospital
Shenzhen University
Sherpa Venture Capital
Shibuya
ShiJiaZhuang Zhongxi Children Hospital
Shinhan Venture Investment
Shionogi
Shiyu Capital
Shoreline Biosciences
Shougang Fund
Sichuan Kelun-Biotech Biopharmaceutical
Sichuan University
Sidney Kimmel Comprehensive Cancer Center
SignalOne Bio
Sigrid Jusélius Foundation
Simcere Pharmaceutical
Sinobioway Cell Therapy
Sino-Singapore Chongqing Connectivity Private Equity Fund Management
Sirona Capital
Sistema
Sixty Degree Capital
SNU Bio Angel
Sofinnova Partners
Soleus Capital
Sorrento Therapeutics
South China Venture Capital
Southern Medical University
Southwest Hospital
SpringWorks Therapeutics
SR One
St. Baldrick's Foundation
St. Jude Children's Research Hospital
Stage Cell Therapeutics
Stand Up To Cancer
Stanford University
Statcom
Steam Athena Capital
STIC Ventures
Stony Brook University
Stratophase
Structured Immunity
Struengmann Family Office
Summer Capital
Sun Yat-sen University
Surveyor Capital
Suvretta Capital Management
Suzhou Porton Biologics
SV Health Investors
Syncona
Syncopation Life Sciences
Syno Capital
Synthace
Syracuse Biopharma
T. Rowe Price Associates
Tactiva Therapeutics
Taiho Ventures and Wu Capital
Takara Bio
Takeda Pharmaceutical
Takeda Ventures
Tangdu Hospital
TC BioPharm
T-Cell Factory
TCR Biotherapeutics
TCR2 Therapeutics
TCRCure Biopharma
TCRyption (Acquired by Treadwell Therapeutics)
T-Cure Bioscience
T-CURX
Tehran University of Medical Sciences
Tekla Capital Management
Tel Aviv Sourasky Medical Center
Temasek
TeneoBio
Teralys Capital
Terra Magnum Capital Partners
Terumo BCT
Tessa Therapeutics
Texas Children's Hospital
TF Capital
The Affiliated Hospital Of Guizhou Medical University
The Affiliated Hospital of Xuzhou Medical University
The Beijing Pregene Science and Technology
The Children's Mercy Hospital
The Coolsingel Foundation
The Faris Foundation
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Guangdong Pharmaceutical University
The First Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Kunming Medical University
The First Affiliated Hospital of Nanchang University
The First Affiliated Hospital of Nanjing Medical University
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of University of Science and Technology of China
The First Affiliated Hospital of Zhejiang University
The First Affiliated Hospital of Zhengzhou University
The First People's Hospital of Hefei
The First People's Hospital of Yuhang District
The First People's Hospital of Yunnan
The Fourth Hospital of Hebei Medical University
The General Hospital of Western Theater Command
The Japanese Society for Regenerative Medicine
The Lind Partners
The Methodist Hospital Research Institute
The Netherlands Cancer Institute
The Ohio State University
The Pregene (ShenZhen) Biotechnology
The Scientific and Technological Research Council of Turkey
The Second Affiliated Hospital of Chongqing Medical University
The Second Affiliated Hospital of Hainan Medical University
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
The Second Affiliated Hospital of Anhui Medical University
The Second Hospital of Hebei Medical University
The Second Affiliated Hospital of Nanjing Medical University
The Seventh Affiliated Hospital, Sun Yat-sen University
The Sixth Affiliated Hospital of Wenzhou Medical University
The Third People's Hospital of Kunshan
The Wistar Institute
Thermo Fisher Scientific
Third Rock Ventures
Tianjin Medical University
Tianjin Medical University General Hospital
Tianjin Mycure Medical Technology
Tianjin Venture Capital
TiCARos
TILT Biotherapeutics
Timmune Biotech
Tiziana Life Sciences
T-knife Therapeutics
Tmunity Therapeutics
Tongji Hospital
Tongji University
Torque Therapeutics
Touchstone Innovations
TrakCel
Transgene
Transposagen Biopharmaceuticals
Treadwell Therapeutics
TriArm Therapeutics
Trinity College Dublin
Tri-Service General Hospital
Triumph Over Kid Cancer Foundation
Triumvira Immunologics
Tscan Therapeutics
Tsinghua University
Turnstone Biologics
Twist Bioscience
TxCell
Tybourne Capital Management
Tzitzit Asset
Ucello Therapeutics
UCL Business
UNC Lineberger Comprehensive Cancer Center
Union Stem Cell & Gene Engineering
US Department of Defense
Universal Cells
University College London
University Health Network
University Hospital Basel
Würzburg University Hospital
University Medical Center Utrecht
University of Alberta
University of Birmingham
University of California
University of Chicago
University of Colorado
University of Connecticut
University of Lausanne
University of Milano-Bicocca
University of Minnesota
University of Montreal
University of Munich
University of North Carolina
University of Oxford
University of Pennsylvania
University of South Australia
University of Southern California
University of Texas
University of Tokyo Hospital
University of Virginia Patent Foundation
University of Washington
University of Washington Cancer Consortium
University of Zurich
UNM Rainforest Innovations
Uppsala University
USHEALTH
UTC Investment
UTC Therapeutics
UWELL Biopharma
V Foundation
VCN Biosciences
Velocity Capital Fintech Ventures
venBio
Versant Ventures
Vertex Pharmaceuticals
VI Ventures
Viking Global Investors
Vineti
Vinnova
ViroMed
Vitruvian Networks
Vivo Capital
Vulpes Investment Management
Washington University
Weill Cornell Medical College
Weill Medical College of Cornell University
Wellington Management
Wellington Zhaotai Therapies
West China Hospital
West China Hospital of Sichuan University
White Rock Capital Management
Woodford Investment Management
Woori Technology Investment
Wugen
Wuhan Bio-Raid Biotechnology
Wuhan Sian Medical Technology
Wuhan Union Hospital
WuXi AppTec
X-Body
Xi'An Yufan Biotechnology
Xiangrong Capital
Xiangxue Life Science Research Center
Xiangxue Pharmaceutical
Xiangya Hospital of Central South University
Xiangyang Central Hospital
Xijing Hospital
Xinhua Hospital
Xinqiao Hospital
Xinqiao Hospital of Chongqing
Xinyi Capital
Xuanwu Hospital
Xuzhou Medical University
Yake Biotechnology
Yamaguchi University
Yan'an Affiliated Hospital of Kunming Medical University
Yeshiva University
Yipu Capital
YuanMing Capital
Yunfeng Capital
Yunnan Cancer Hospital
Zelluna Immunotherapy
Zhejiang Huahai Pharmaceutical
Zhejiang Provincial People's Hospital
Zhejiang Qixin Biotech
Zhejiang University

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5764EUR$5,899USD£4,812GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7815EUR$7,999USD£6,525GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€17586EUR$17,999USD£14,681GBP

Scope of the Report

The report features detailed transcripts of interviews held with the following individuals:

Key Questions Answered

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography

CAR T Cell Therapy Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication, Target Antigens, Key Geographical Regions, Key Players and Sales Forecast

T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030

CAR T-Cell Therapy for Multiple Myeloma - Market Insight, Epidemiology and Market Forecast - 2034